
Alexander M Popov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2820929/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Relative expansion of CD19â€negative veryâ€early normal Bâ€cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CARâ€T cell therapy: implications for flow cytometric detection of minimal residual disease. British Journal of Haematology, 2021, 193, 602-612.	1.2	30
2	Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1331-1339.	1.2	24
3	An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report. Cancers, 2021, 13, 6148.	1.7	24
4	Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia who have been treated with blinatumomab. Haematologica, 2021, 106, 2009-2012.	1.7	18
5	Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy. International Journal of Molecular Sciences, 2022, 23, 4019.	1.8	18
6	Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 535-542.	1.2	15
7	Highâ€throughput sequencing of Tâ€cell receptor alpha chain clonal rearrangements at the DNA level in lymphoid malignancies. British Journal of Haematology, 2020, 188, 723-731.	1.2	13
8	Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols. Leukemia, 2020, 34, 3042-3046.	3.3	13
9	An inter-laboratory comparison of PNH clone detection by high-sensitivity flow cytometry in a Russian cohort. Hematology, 2015, 20, 31-38.	0.7	12
10	Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR. Pediatric Blood and Cancer, 2018, 65, e27354.	0.8	12
11	Chimerism evaluation in measurable residual diseaseâ€suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Cytometry Part B - Clinical Cytometry, 2021, 100, 568-573.	0.7	12
12	Bâ€lineage antigens that are useful to substitute <scp>CD19</scp> for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after <scp>CD19</scp> targeting. Cytometry Part B - Clinical Cytometry, 2022, 102, 353-359.	0.7	11
13	Quantification of NG2 â€positivity for the precise prediction of KMT2A gene rearrangements in childhood acute leukemia. Genes Chromosomes and Cancer, 2021, 60, 88-99.	1.5	8
14	Blinatumomab following haematopoietic stem cell transplantation – a novel approach for the treatment of acute lymphoblastic leukaemia in infants. British Journal of Haematology, 2021, 194, 174-178.	1.2	8
15	Prognostic value of minimal residual disease measured by fusionâ€gene transcript in infants with <i>KMT2A</i> â€rearranged acute lymphoblastic leukaemia treated according to the MLLâ€Baby protocol. British Journal of Haematology, 2021, 193, 1151-1156.	1.2	8
16	Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with <i>KMT2A</i> gene rearrangements. British Journal of Haematology, 2023, 201, 510-519.	1.2	8
17	Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia. Blood Advances, 2023, 7, 953-962.	2.5	8
18	Heterogeneity of childhood acute leukemia with mature B-cell immunophenotype. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2803-2811.	1.2	7

#	Article	IF	CITATIONS
19	Strong expansion of normal CD19â€negative Bâ€cell precursors after the use of blinatumomab in the firstâ€line therapy of acute lymphoblastic leukaemia in children. British Journal of Haematology, 2022, 196, .	1.2	6
20	Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells. Haematologica, 2022, 107, 970-974.	1.7	6
21	A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results. Leukemia, 2022, 36, 1382-1385.	3.3	6
22	Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report. Leukemia Research, 2022, 112, 106758.	0.4	5
23	Additional flow cytometric studies for differential diagnosis between Burkitt lymphoma/leukemia and B-cell precursor acute lymphoblastic leukemia. Leukemia Research, 2021, 100, 106491.	0.4	3
24	Immune reconstitution following rituximab-based immunochemotherapy in pediatric patients with B-cell non-Hodgkin lymphomas. Leukemia and Lymphoma, 2022, 63, 217-221.	0.6	3
25	Incidence and prognostic value of central nervous system involvement in infants with B ell precursor acute lymphoblastic leukemia treated according to the MLLâ€Baby protocol. Pediatric Blood and Cancer, 2022, 69, .	0.8	3
26	Does ATRA Confirm to Play a Role in the Better Relapse Free Survival of Infants with Acute Lymphoblastic Leukemia?. Blood, 2011, 118, 1515-1515.	0.6	2
27	The use of additional immunophenotypic criteria for the differential diagnosis of Burkitt lymphoma/leukemia: An exemplary case report. Leukemia Research, 2021, 110, 106662.	0.4	1